Same Sky

The Stecher and Horowitz Foundation considers itself an incubator of talent in the world of classical music. It serves as a conduit to discover, uncover, and present these remarkable young pianists to an audience awaiting the latest musical gems to be unearthed. This concept was inspired by the inquisitive faces we saw pass through the doors of the Stecher and Horowitz School of the Arts for 39 years, in Cedarhurst, New York. Concerned about the road that lay ahead for the many aspiring musicians we trained, we realized that the next chapter in the Foundation's mission was the need to serve as mentors through the flagship program, The New York International Piano Competition. This would create opportunities for these amazing young artists who often lack the means and know-how to pursue a career.

The Egyptian-American Enterprise Fund (EAEF) is a private independent entity that plays a crucial role in rebuilding Egypt's private sector after the revolution. Since its establishment in 2011, EAEF has supported the growth of top private equity and venture capital firms in the Middle East, expanded access to financial services for 49 million Egyptians, and created 40,000 jobs. With its partners, EAEF has catalyzed over $1 billion in foreign investment, contributing to Egypt's long-term economic growth. EAEF operates under the guidance of an experienced board of directors, consisting of private sector professionals from the United States and Egypt. The organization's efforts focus on supporting Egypt's private sector during challenging times, leveraging international investment expertise to strengthen the country's economy and promote the growth of the private sector. Through its impactful initiatives, EAEF aims to contribute to Egypt's economic development and create a sustainable future for the nation.Generated from the website

The Spinal Muscular Atrophy Foundation is a non-profit organization based in New York, NY, dedicated to expediting the development of treatments for Spinal Muscular Atrophy (SMA), the leading genetic cause of death in young children. With 1 in 50 people being carriers of the disease, the foundation aims to raise awareness and support research efforts to combat SMA. They have successfully facilitated the approval of three FDA drugs and continue to drive clinical trials for further advancements. The foundation recently mourned the loss of Steve Mikita, a valued member of their board of directors, highlighting their commitment to the cause and the personal connections they foster within their organization. As they strive to make a difference in the lives of those affected by SMA, the Spinal Muscular Atrophy Foundation remains dedicated to their mission of accelerating treatment development and improving outcomes for individuals with this debilitating condition.Generated from the website